Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy

Naoto Miyanaga, Hideyuki Akaza, Shiro Hinotsu, Akira Joraku, Takehiro Oikawa, Noritoshi Sekido, Koji Kawai, Toru Shimazui

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objective: The present study was undertaken to identify the patients suitable for bladder preservation by analysis of our data. Methods: The subjects of this study were all 72 patients with T2-3N0M0 bladder cancer who underwent bladder-preserving therapy in our institute. The therapy involved intra-arterial chemotherapy with MTX and CDDP and concomitant radiotherapy. Results: Of the evaluable 70 cases, complete response (CR) was confirmed in 57 cases (81.4%). Among 56 bladder preserved cases, 47 (83.9%) preserved their functioning bladder, and 9 underwent salvage radical cystectomy at the following period. The median follow-up was 45.3 months. The 5-year cause-specific survival rate was 81% and the 5-year overall survival rate was 66%. On the basis of the results of univariate analysis, variables contributing to CR were selected. In T2, tumor size of ≤3 cm was scored 0 and >3 cm was scored 1, whereas single tumor was scored 0 and multiple were scored 1. In T3, tumor size of ≤3 cm was scored 0 and >3 cm was scored 1, whereas G2 was scored 0 and G3 scored 1. The CR rates were 93.8, 92.6, and 62.9% for total scores of 0, 1, and 2, respectively (P = 0.003; score 0 or 1 versus 2). The overall survival rate was significantly higher in the former group (P = 0.003). Conclusion: Bladder-preserving therapy can be acceptable for cases of single T2N0M0 tumor with a size of ≤3 cm and for T3N0M0 cases with a tumor size of ≤3 cm.

Original languageEnglish
Pages (from-to)852-857
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume37
Issue number11
DOIs
Publication statusPublished - Nov 2007
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Urinary Bladder
Survival Rate
Neoplasms
Therapeutics
Cystectomy
Radiotherapy
Drug Therapy

Keywords

  • Bladder preservation
  • Chemotherapy
  • Invasive bladder cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Miyanaga, N., Akaza, H., Hinotsu, S., Joraku, A., Oikawa, T., Sekido, N., ... Shimazui, T. (2007). Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy. Japanese Journal of Clinical Oncology, 37(11), 852-857. https://doi.org/10.1093/jjco/hym129

Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy. / Miyanaga, Naoto; Akaza, Hideyuki; Hinotsu, Shiro; Joraku, Akira; Oikawa, Takehiro; Sekido, Noritoshi; Kawai, Koji; Shimazui, Toru.

In: Japanese Journal of Clinical Oncology, Vol. 37, No. 11, 11.2007, p. 852-857.

Research output: Contribution to journalArticle

Miyanaga, N, Akaza, H, Hinotsu, S, Joraku, A, Oikawa, T, Sekido, N, Kawai, K & Shimazui, T 2007, 'Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy', Japanese Journal of Clinical Oncology, vol. 37, no. 11, pp. 852-857. https://doi.org/10.1093/jjco/hym129
Miyanaga, Naoto ; Akaza, Hideyuki ; Hinotsu, Shiro ; Joraku, Akira ; Oikawa, Takehiro ; Sekido, Noritoshi ; Kawai, Koji ; Shimazui, Toru. / Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy. In: Japanese Journal of Clinical Oncology. 2007 ; Vol. 37, No. 11. pp. 852-857.
@article{7b164e02aad644eea87bbe506fdea6d0,
title = "Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy",
abstract = "Objective: The present study was undertaken to identify the patients suitable for bladder preservation by analysis of our data. Methods: The subjects of this study were all 72 patients with T2-3N0M0 bladder cancer who underwent bladder-preserving therapy in our institute. The therapy involved intra-arterial chemotherapy with MTX and CDDP and concomitant radiotherapy. Results: Of the evaluable 70 cases, complete response (CR) was confirmed in 57 cases (81.4{\%}). Among 56 bladder preserved cases, 47 (83.9{\%}) preserved their functioning bladder, and 9 underwent salvage radical cystectomy at the following period. The median follow-up was 45.3 months. The 5-year cause-specific survival rate was 81{\%} and the 5-year overall survival rate was 66{\%}. On the basis of the results of univariate analysis, variables contributing to CR were selected. In T2, tumor size of ≤3 cm was scored 0 and >3 cm was scored 1, whereas single tumor was scored 0 and multiple were scored 1. In T3, tumor size of ≤3 cm was scored 0 and >3 cm was scored 1, whereas G2 was scored 0 and G3 scored 1. The CR rates were 93.8, 92.6, and 62.9{\%} for total scores of 0, 1, and 2, respectively (P = 0.003; score 0 or 1 versus 2). The overall survival rate was significantly higher in the former group (P = 0.003). Conclusion: Bladder-preserving therapy can be acceptable for cases of single T2N0M0 tumor with a size of ≤3 cm and for T3N0M0 cases with a tumor size of ≤3 cm.",
keywords = "Bladder preservation, Chemotherapy, Invasive bladder cancer, Radiotherapy",
author = "Naoto Miyanaga and Hideyuki Akaza and Shiro Hinotsu and Akira Joraku and Takehiro Oikawa and Noritoshi Sekido and Koji Kawai and Toru Shimazui",
year = "2007",
month = "11",
doi = "10.1093/jjco/hym129",
language = "English",
volume = "37",
pages = "852--857",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy

AU - Miyanaga, Naoto

AU - Akaza, Hideyuki

AU - Hinotsu, Shiro

AU - Joraku, Akira

AU - Oikawa, Takehiro

AU - Sekido, Noritoshi

AU - Kawai, Koji

AU - Shimazui, Toru

PY - 2007/11

Y1 - 2007/11

N2 - Objective: The present study was undertaken to identify the patients suitable for bladder preservation by analysis of our data. Methods: The subjects of this study were all 72 patients with T2-3N0M0 bladder cancer who underwent bladder-preserving therapy in our institute. The therapy involved intra-arterial chemotherapy with MTX and CDDP and concomitant radiotherapy. Results: Of the evaluable 70 cases, complete response (CR) was confirmed in 57 cases (81.4%). Among 56 bladder preserved cases, 47 (83.9%) preserved their functioning bladder, and 9 underwent salvage radical cystectomy at the following period. The median follow-up was 45.3 months. The 5-year cause-specific survival rate was 81% and the 5-year overall survival rate was 66%. On the basis of the results of univariate analysis, variables contributing to CR were selected. In T2, tumor size of ≤3 cm was scored 0 and >3 cm was scored 1, whereas single tumor was scored 0 and multiple were scored 1. In T3, tumor size of ≤3 cm was scored 0 and >3 cm was scored 1, whereas G2 was scored 0 and G3 scored 1. The CR rates were 93.8, 92.6, and 62.9% for total scores of 0, 1, and 2, respectively (P = 0.003; score 0 or 1 versus 2). The overall survival rate was significantly higher in the former group (P = 0.003). Conclusion: Bladder-preserving therapy can be acceptable for cases of single T2N0M0 tumor with a size of ≤3 cm and for T3N0M0 cases with a tumor size of ≤3 cm.

AB - Objective: The present study was undertaken to identify the patients suitable for bladder preservation by analysis of our data. Methods: The subjects of this study were all 72 patients with T2-3N0M0 bladder cancer who underwent bladder-preserving therapy in our institute. The therapy involved intra-arterial chemotherapy with MTX and CDDP and concomitant radiotherapy. Results: Of the evaluable 70 cases, complete response (CR) was confirmed in 57 cases (81.4%). Among 56 bladder preserved cases, 47 (83.9%) preserved their functioning bladder, and 9 underwent salvage radical cystectomy at the following period. The median follow-up was 45.3 months. The 5-year cause-specific survival rate was 81% and the 5-year overall survival rate was 66%. On the basis of the results of univariate analysis, variables contributing to CR were selected. In T2, tumor size of ≤3 cm was scored 0 and >3 cm was scored 1, whereas single tumor was scored 0 and multiple were scored 1. In T3, tumor size of ≤3 cm was scored 0 and >3 cm was scored 1, whereas G2 was scored 0 and G3 scored 1. The CR rates were 93.8, 92.6, and 62.9% for total scores of 0, 1, and 2, respectively (P = 0.003; score 0 or 1 versus 2). The overall survival rate was significantly higher in the former group (P = 0.003). Conclusion: Bladder-preserving therapy can be acceptable for cases of single T2N0M0 tumor with a size of ≤3 cm and for T3N0M0 cases with a tumor size of ≤3 cm.

KW - Bladder preservation

KW - Chemotherapy

KW - Invasive bladder cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=37149007272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37149007272&partnerID=8YFLogxK

U2 - 10.1093/jjco/hym129

DO - 10.1093/jjco/hym129

M3 - Article

C2 - 17965422

AN - SCOPUS:37149007272

VL - 37

SP - 852

EP - 857

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 11

ER -